July 13, 2020
As per the report titled ‘Global Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 ? 2024)’, available with Market Study Report LLC, global Prader-Willi syndrome (PWS) therapeutics market is projected to record a year-over-year growth rate of 4.6% through 2024.
Rising cases of patients diagnosed with Prader-Willi syndrome, increase in coverage rate of human growth hormone therapy, growing awareness, and increased government efforts towards addressing this disorder are fueling the growth of Prader-Will syndrome therapeutics market, cites the report.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2237736/
Further, emergence of various novel therapies, including DCCR (Soleno Therapeutics), Testomet (Saniona AB), and Livoletide (Millendo Therapeutics) among others which are undergoing pipeline analysis is expected to propel the growth of global Prader-Willi syndrome therapeutics market in the forthcoming years.
Considering the regional landscape, global Prader-Willi syndrome market is divided into United States, Germany, France, United Kingdom, and Japan.
Some of the renowned players in worldwide Prader-Willi syndrome therapeutics industry are Saniona, Soleno Therapeutics, Novo Nordisk, Novartis AG, and Pfizer. The report entails strategic recommendations like investment in combination therapy for PWS and somatropic biosimilar to enable industry majors in diversifying their product portfolio and improve revenues.